RAPS is closely monitoring developments in the Coronavirus (COVID-19) outbreak. See our public safety page for the latest updates.

Regulatory Focus™ > News Articles > Regulatory Manager: EU Regulations for Clinical Studies in Pediatric Patients

Regulatory Manager: EU Regulations for Clinical Studies in Pediatric Patients

Posted 01 November 2010 | By

In 2006, the European Council (EC) and the European Parliament adopted a regulation that created major changes in the way clinical studies in pediatric patients would be planned and conducted in the EU.1 For many years, clinical evaluations of drugs and biologics were conducted primarily in adults because it was simpler and raised fewer ethical concerns than conducting studies in children. Nevertheless, following regulatory approval for use in adults, these products were often prescribed for children despite the lack of clinical trials in this population. Physicians often used an empirically selected lower dose based on the weight of the child. In some cases, this could have resulted in exposure to unsafe or ineffective doses because children may metabolize a drug or biologic differently than do adults.

Regulatory Focus newsletters

All the biggest regulatory news and happenings.

Subscribe

Regulatory Focus™ is doing essential, non-biased journalism during this unprecedented time. We appreciate your support as we bring you the news and intelligence you need to make an impact on global healthcare.

Regulatory Focus™ provides the intelligence you need to impact global healthcare during this crisis. Thank you for your support.